Trial Profile
Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq - A Canadian Study
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms PREVAIL
- Sponsors Octapharma
- 12 Feb 2021 Status changed from recruiting to discontinued.(Study terminated as enrolled patients rolled over into a large international study in the same indication )
- 19 Jul 2018 Status changed from not yet recruiting to recruiting.
- 05 Jun 2018 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.